STOCK TITAN

PharmaTher Holdings Ltd - PHRRF STOCK NEWS

Welcome to our dedicated news page for PharmaTher Holdings (Ticker: PHRRF), a resource for investors and traders seeking the latest updates and insights on PharmaTher Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PharmaTher Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PharmaTher Holdings's position in the market.

Rhea-AI Summary
PharmaTher Holdings Ltd. announced that its subsidiary, Sairiyo Therapeutics Inc., has initiated a Phase 1 clinical study in Australia for its patented reformulated version of cepharanthine, PD-001, to treat oncology and infectious diseases. Sairiyo is set to benefit from drug development incentives in Australia and aims to manufacture clinical batches by Q2-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
clinical trial
-
Rhea-AI Summary
PharmaTher Holdings Ltd. provides an update on its Priority Original Abbreviated New Drug Application for Ketamine accepted by the FDA. The Company aims to address possible deficiencies before the goal date of April 29, 2024, to solve the ketamine shortage problem in the U.S. and pursue international approvals. Ketamine, an essential medicine, is being used for various mental health, neurological, and pain disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.1%
Tags
none
-
Rhea-AI Summary
PharmaTher Holdings Ltd. (PHRRF) is on track to receive FDA approval for its lead drug, ketamine, with an assigned approval goal date of April 29, 2024. The company aims to address the ketamine shortage problem in the U.S. and anticipates the commercial launch of ketamine in 2024, followed by international approvals. Ketamine has potential applications in anesthesia, sedation, pain, mental health, and neurological disorders, with recent studies demonstrating its effectiveness in treating depression, anxiety, and suicidal ideation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
fda approval
Rhea-AI Summary
PharmaTher's KETARX™ (racemic ketamine) receives FDA acceptance for Abbreviated New Drug Application (ANDA) with a goal date of April 29, 2024. Commercial launch in the U.S. expected after that, followed by pursuit of international approvals. Ketamine's potential for mental health, neurological, and pain disorders gaining momentum. Recently published study shows significant patient improvement. Partnership with Vitruvias Therapeutics to commercialize KETARX™ in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
clinical trial
-
Rhea-AI Summary
PharmaTher submits priority original ANDA for KETARX to FDA, anticipates approval and commercial launch in Q2-2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
none
Rhea-AI Summary
PharmaTher Holdings has filed a Pre-Submission Facility Correspondence to support expedited review of its priority ANDA for KETARX™ (racemic ketamine). The company anticipates FDA approval in Q1-2024 and commercial launch in Q2-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.82%
Tags
none
-
Rhea-AI Summary
PharmaTher Holdings has entered into a collaboration agreement with Vitruvias Therapeutics for the commercialization of its KETARX products in the US. The company expects to file its abbreviated new drug application for KETARX with the FDA in July 2023 and obtain FDA approval in Q1-2024. The commercial launch is anticipated in Q2-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.23%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
none
PharmaTher Holdings Ltd

OTC:PHRRF

PHRRF Rankings

PHRRF Stock Data

25.88M
71.67M
18.69%
0.06%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Toronto